Cancer therapeutics and diagnostics - MabCure

Drug Profile

Cancer therapeutics and diagnostics - MabCure

Alternative Names: anti-PROSCA; anti-PROSCA monoclonal antibodies

Latest Information Update: 16 Apr 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MabCure
  • Class Antibody diagnostics; Diagnostic agents; Monoclonal antibodies; Monoclonal antibody diagnostics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Ovarian cancer
  • Preclinical Cancer
  • Research Colorectal cancer; Malignant melanoma; Prostate cancer

Most Recent Events

  • 12 Apr 2012 Monoclonal antibodies licensed to Biotech Investment Corporation worldwide for the diagnosis and treatment of prostate cancer
  • 20 Mar 2012 This research programme is still in active development
  • 22 Nov 2011 Early research for Prostate cancer (diagnosis) in Belgium (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top